Related Experiment Video

Updated: May 4, 2026

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation
08:47

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation

Published on: March 5, 2018

8.5K

Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity

Rachel C Botham1, Timothy M Fan, Isak Im

  • 1Department of Chemistry, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States.

Journal of the American Chemical Society
|January 4, 2014
PubMed

Insights

This study introduces a novel combination anticancer therapy using two procaspase-3 activators, PAC-1 and 1541B. Their synergistic action enhances cancer cell death and reduces tumor burden, offering a promising new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Combination anticancer therapy often targets different pathways or targets.
  • A novel strategy involves enzyme activation using compounds with different mechanisms on the same target.

Purpose of the Study:

  • To explore the synergistic potential of combining procaspase-3 activators PAC-1 and 1541B.
  • To evaluate the efficacy of this combination in cancer cell lines and a murine lymphoma model.

Main Methods:

  • In vitro activation of procaspase-3 by PAC-1 and 1541B.
  • Assessment of procaspase-3 maturation and caspase-dependent apoptosis in cancer cell lines.
  • Evaluation of tumor burden reduction in a murine lymphoma model.

Main Results:

  • PAC-1 and 1541B demonstrated significant synergy in activating procaspase-3 in vitro.
  • The combination induced rapid procaspase-3 maturation and potent caspase-dependent apoptosis in cancer cells.
  • Combined PAC-1 and 1541B effectively reduced tumor burden in mice at low dosages.

Conclusions:

  • Differentially acting enzyme activators can achieve potent synergy for heightened biological effects.
  • The PAC-1/1541B combination shows potential for cancer treatment.
  • This approach broadens the concept of combination anticancer therapy.

More Related Videos

Measuring Caspase Activity Using a Fluorometric Assay or Flow Cytometry05:29

Measuring Caspase Activity Using a Fluorometric Assay or Flow Cytometry

Published on: March 24, 2023

7.7K
In Vitro Cleavage Assays using Purified Recombinant Drosophila Caspases for Substrate Screening08:16

In Vitro Cleavage Assays using Purified Recombinant Drosophila Caspases for Substrate Screening

Published on: October 6, 2022

2.6K

Related Concept Videos

Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
8.7K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
12.0K